Compile Data Set for Download or QSAR
Report error Found 72 Enz. Inhib. hit(s) with all data for entry = 8851
TargetIndoleamine 2,3-dioxygenase 1(Human)
Iomet Pharma

US Patent
LigandChemical structure of BindingDB Monomer ID 423348BDBM423348(US10501458, Compound 1021)
Affinity DataIC50: 158nMAssay Description:Compounds to be tested were serially diluted in ten 3-fold steps in DMSO starting from 10 mM DMSO stocks. Compound dilutions or DMSO alone were then ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/12/2020
Entry Details
US Patent

TargetIndoleamine 2,3-dioxygenase 1(Human)
Iomet Pharma

US Patent
LigandChemical structure of BindingDB Monomer ID 423362BDBM423362(3-methyl-5-{1-[7- (trifluoromethyl)imidazo[1, 5-a]...)
Affinity DataIC50: 251nMAssay Description:Compounds to be tested were serially diluted in ten 3-fold steps in DMSO starting from 10 mM DMSO stocks. Compound dilutions or DMSO alone were then ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/12/2020
Entry Details
US Patent

TargetTryptophan 2,3-dioxygenase(Human)
Iomet Pharma

US Patent
LigandChemical structure of BindingDB Monomer ID 423359BDBM423359(US10501458, Compound 1032)
Affinity DataIC50: 300nMAssay Description:Recombinant human IDO or TDO was incubated in 50 mM KPO4 (pH 7.0), 0.5 mM EGTA, 0.5 mM EDTA, 0.05% Triton X100, 20 mM ascorbate, 10 μM methylene...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/12/2020
Entry Details
US Patent

TargetIndoleamine 2,3-dioxygenase 1(Human)
Iomet Pharma

US Patent
LigandChemical structure of BindingDB Monomer ID 423358BDBM423358(US10501458, Compound 1031)
Affinity DataIC50: 300nMAssay Description:Recombinant human IDO or TDO was incubated in 50 mM KPO4 (pH 7.0), 0.5 mM EGTA, 0.5 mM EDTA, 0.05% Triton X100, 20 mM ascorbate, 10 μM methylene...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/12/2020
Entry Details
US Patent

TargetTryptophan 2,3-dioxygenase(Human)
Iomet Pharma

US Patent
LigandChemical structure of BindingDB Monomer ID 423360BDBM423360(US10501458, Compound 1033)
Affinity DataIC50: 300nMAssay Description:Recombinant human IDO or TDO was incubated in 50 mM KPO4 (pH 7.0), 0.5 mM EGTA, 0.5 mM EDTA, 0.05% Triton X100, 20 mM ascorbate, 10 μM methylene...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/12/2020
Entry Details
US Patent

TargetIndoleamine 2,3-dioxygenase 1(Human)
Iomet Pharma

US Patent
LigandChemical structure of BindingDB Monomer ID 423359BDBM423359(US10501458, Compound 1032)
Affinity DataIC50: 300nMAssay Description:Recombinant human IDO or TDO was incubated in 50 mM KPO4 (pH 7.0), 0.5 mM EGTA, 0.5 mM EDTA, 0.05% Triton X100, 20 mM ascorbate, 10 μM methylene...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/12/2020
Entry Details
US Patent

TargetTryptophan 2,3-dioxygenase(Human)
Iomet Pharma

US Patent
LigandChemical structure of BindingDB Monomer ID 423357BDBM423357(US10501458, Compound 1030)
Affinity DataIC50: 300nMAssay Description:Recombinant human IDO or TDO was incubated in 50 mM KPO4 (pH 7.0), 0.5 mM EGTA, 0.5 mM EDTA, 0.05% Triton X100, 20 mM ascorbate, 10 μM methylene...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/12/2020
Entry Details
US Patent

TargetIndoleamine 2,3-dioxygenase 1(Human)
Iomet Pharma

US Patent
LigandChemical structure of BindingDB Monomer ID 423356BDBM423356(US10501458, Compound 1029)
Affinity DataIC50: 300nMAssay Description:Recombinant human IDO or TDO was incubated in 50 mM KPO4 (pH 7.0), 0.5 mM EGTA, 0.5 mM EDTA, 0.05% Triton X100, 20 mM ascorbate, 10 μM methylene...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/12/2020
Entry Details
US Patent

TargetTryptophan 2,3-dioxygenase(Human)
Iomet Pharma

US Patent
LigandChemical structure of BindingDB Monomer ID 423358BDBM423358(US10501458, Compound 1031)
Affinity DataIC50: 300nMAssay Description:Recombinant human IDO or TDO was incubated in 50 mM KPO4 (pH 7.0), 0.5 mM EGTA, 0.5 mM EDTA, 0.05% Triton X100, 20 mM ascorbate, 10 μM methylene...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/12/2020
Entry Details
US Patent

TargetIndoleamine 2,3-dioxygenase 1(Human)
Iomet Pharma

US Patent
LigandChemical structure of BindingDB Monomer ID 423357BDBM423357(US10501458, Compound 1030)
Affinity DataIC50: 300nMAssay Description:Recombinant human IDO or TDO was incubated in 50 mM KPO4 (pH 7.0), 0.5 mM EGTA, 0.5 mM EDTA, 0.05% Triton X100, 20 mM ascorbate, 10 μM methylene...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/12/2020
Entry Details
US Patent

TargetTryptophan 2,3-dioxygenase(Human)
Iomet Pharma

US Patent
LigandChemical structure of BindingDB Monomer ID 423355BDBM423355(US10501458, Compound 1028)
Affinity DataIC50: 300nMAssay Description:Recombinant human IDO or TDO was incubated in 50 mM KPO4 (pH 7.0), 0.5 mM EGTA, 0.5 mM EDTA, 0.05% Triton X100, 20 mM ascorbate, 10 μM methylene...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/12/2020
Entry Details
US Patent

TargetTryptophan 2,3-dioxygenase(Human)
Iomet Pharma

US Patent
LigandChemical structure of BindingDB Monomer ID 423356BDBM423356(US10501458, Compound 1029)
Affinity DataIC50: 300nMAssay Description:Recombinant human IDO or TDO was incubated in 50 mM KPO4 (pH 7.0), 0.5 mM EGTA, 0.5 mM EDTA, 0.05% Triton X100, 20 mM ascorbate, 10 μM methylene...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/12/2020
Entry Details
US Patent

TargetTryptophan 2,3-dioxygenase(Human)
Iomet Pharma

US Patent
LigandChemical structure of BindingDB Monomer ID 423353BDBM423353(US10501458, Compound 1026)
Affinity DataIC50: 300nMAssay Description:Recombinant human IDO or TDO was incubated in 50 mM KPO4 (pH 7.0), 0.5 mM EGTA, 0.5 mM EDTA, 0.05% Triton X100, 20 mM ascorbate, 10 μM methylene...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/12/2020
Entry Details
US Patent

TargetIndoleamine 2,3-dioxygenase 1(Human)
Iomet Pharma

US Patent
LigandChemical structure of BindingDB Monomer ID 423352BDBM423352(US10501458, Compound 1025)
Affinity DataIC50: 300nMAssay Description:Recombinant human IDO or TDO was incubated in 50 mM KPO4 (pH 7.0), 0.5 mM EGTA, 0.5 mM EDTA, 0.05% Triton X100, 20 mM ascorbate, 10 μM methylene...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/12/2020
Entry Details
US Patent

TargetTryptophan 2,3-dioxygenase(Human)
Iomet Pharma

US Patent
LigandChemical structure of BindingDB Monomer ID 423354BDBM423354(US10501458, Compound 1027)
Affinity DataIC50: 300nMAssay Description:Recombinant human IDO or TDO was incubated in 50 mM KPO4 (pH 7.0), 0.5 mM EGTA, 0.5 mM EDTA, 0.05% Triton X100, 20 mM ascorbate, 10 μM methylene...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/12/2020
Entry Details
US Patent

TargetIndoleamine 2,3-dioxygenase 1(Human)
Iomet Pharma

US Patent
LigandChemical structure of BindingDB Monomer ID 423353BDBM423353(US10501458, Compound 1026)
Affinity DataIC50: 300nMAssay Description:Recombinant human IDO or TDO was incubated in 50 mM KPO4 (pH 7.0), 0.5 mM EGTA, 0.5 mM EDTA, 0.05% Triton X100, 20 mM ascorbate, 10 μM methylene...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/12/2020
Entry Details
US Patent

TargetTryptophan 2,3-dioxygenase(Human)
Iomet Pharma

US Patent
LigandChemical structure of BindingDB Monomer ID 423334BDBM423334(US10501458, Compound 1007)
Affinity DataIC50: 300nMAssay Description:Recombinant human IDO or TDO was incubated in 50 mM KPO4 (pH 7.0), 0.5 mM EGTA, 0.5 mM EDTA, 0.05% Triton X100, 20 mM ascorbate, 10 μM methylene...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/12/2020
Entry Details
US Patent

TargetTryptophan 2,3-dioxygenase(Human)
Iomet Pharma

US Patent
LigandChemical structure of BindingDB Monomer ID 423332BDBM423332(US10501458, Compound 1005)
Affinity DataIC50: 300nMAssay Description:Recombinant human IDO or TDO was incubated in 50 mM KPO4 (pH 7.0), 0.5 mM EGTA, 0.5 mM EDTA, 0.05% Triton X100, 20 mM ascorbate, 10 μM methylene...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/12/2020
Entry Details
US Patent

TargetTryptophan 2,3-dioxygenase(Human)
Iomet Pharma

US Patent
LigandChemical structure of BindingDB Monomer ID 423333BDBM423333(US10501458, Compound 1006)
Affinity DataIC50: 300nMAssay Description:Recombinant human IDO or TDO was incubated in 50 mM KPO4 (pH 7.0), 0.5 mM EGTA, 0.5 mM EDTA, 0.05% Triton X100, 20 mM ascorbate, 10 μM methylene...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/12/2020
Entry Details
US Patent

TargetTryptophan 2,3-dioxygenase(Human)
Iomet Pharma

US Patent
LigandChemical structure of BindingDB Monomer ID 423328BDBM423328(US10501458, Compound 1003)
Affinity DataIC50: 300nMAssay Description:Recombinant human IDO or TDO was incubated in 50 mM KPO4 (pH 7.0), 0.5 mM EGTA, 0.5 mM EDTA, 0.05% Triton X100, 20 mM ascorbate, 10 μM methylene...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/12/2020
Entry Details
US Patent

TargetTryptophan 2,3-dioxygenase(Human)
Iomet Pharma

US Patent
LigandChemical structure of BindingDB Monomer ID 423331BDBM423331(US10501458, Compound 1004)
Affinity DataIC50: 300nMAssay Description:Recombinant human IDO or TDO was incubated in 50 mM KPO4 (pH 7.0), 0.5 mM EGTA, 0.5 mM EDTA, 0.05% Triton X100, 20 mM ascorbate, 10 μM methylene...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/12/2020
Entry Details
US Patent

TargetIndoleamine 2,3-dioxygenase 1(Human)
Iomet Pharma

US Patent
LigandChemical structure of BindingDB Monomer ID 423360BDBM423360(US10501458, Compound 1033)
Affinity DataIC50: 300nMAssay Description:Recombinant human IDO or TDO was incubated in 50 mM KPO4 (pH 7.0), 0.5 mM EGTA, 0.5 mM EDTA, 0.05% Triton X100, 20 mM ascorbate, 10 μM methylene...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/12/2020
Entry Details
US Patent

TargetTryptophan 2,3-dioxygenase(Human)
Iomet Pharma

US Patent
LigandChemical structure of BindingDB Monomer ID 423327BDBM423327(US10501458, Compound 1002)
Affinity DataIC50: 300nMAssay Description:Recombinant human IDO or TDO was incubated in 50 mM KPO4 (pH 7.0), 0.5 mM EGTA, 0.5 mM EDTA, 0.05% Triton X100, 20 mM ascorbate, 10 μM methylene...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/12/2020
Entry Details
US Patent

TargetTryptophan 2,3-dioxygenase(Human)
Iomet Pharma

US Patent
LigandChemical structure of BindingDB Monomer ID 423343BDBM423343(US10501458, Compound 1016)
Affinity DataIC50: 300nMAssay Description:Recombinant human IDO or TDO was incubated in 50 mM KPO4 (pH 7.0), 0.5 mM EGTA, 0.5 mM EDTA, 0.05% Triton X100, 20 mM ascorbate, 10 μM methylene...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/12/2020
Entry Details
US Patent

TargetIndoleamine 2,3-dioxygenase 1(Human)
Iomet Pharma

US Patent
LigandChemical structure of BindingDB Monomer ID 423343BDBM423343(US10501458, Compound 1016)
Affinity DataIC50: 300nMAssay Description:Recombinant human IDO or TDO was incubated in 50 mM KPO4 (pH 7.0), 0.5 mM EGTA, 0.5 mM EDTA, 0.05% Triton X100, 20 mM ascorbate, 10 μM methylene...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/12/2020
Entry Details
US Patent

TargetTryptophan 2,3-dioxygenase(Human)
Iomet Pharma

US Patent
LigandChemical structure of BindingDB Monomer ID 423341BDBM423341(US10501458, Compound 1014)
Affinity DataIC50: 300nMAssay Description:Recombinant human IDO or TDO was incubated in 50 mM KPO4 (pH 7.0), 0.5 mM EGTA, 0.5 mM EDTA, 0.05% Triton X100, 20 mM ascorbate, 10 μM methylene...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/12/2020
Entry Details
US Patent

TargetIndoleamine 2,3-dioxygenase 1(Human)
Iomet Pharma

US Patent
LigandChemical structure of BindingDB Monomer ID 423341BDBM423341(US10501458, Compound 1014)
Affinity DataIC50: 300nMAssay Description:Recombinant human IDO or TDO was incubated in 50 mM KPO4 (pH 7.0), 0.5 mM EGTA, 0.5 mM EDTA, 0.05% Triton X100, 20 mM ascorbate, 10 μM methylene...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/12/2020
Entry Details
US Patent

TargetTryptophan 2,3-dioxygenase(Human)
Iomet Pharma

US Patent
LigandChemical structure of BindingDB Monomer ID 423339BDBM423339(US10501458, Compound 1012)
Affinity DataIC50: 300nMAssay Description:Recombinant human IDO or TDO was incubated in 50 mM KPO4 (pH 7.0), 0.5 mM EGTA, 0.5 mM EDTA, 0.05% Triton X100, 20 mM ascorbate, 10 μM methylene...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/12/2020
Entry Details
US Patent

TargetTryptophan 2,3-dioxygenase(Human)
Iomet Pharma

US Patent
LigandChemical structure of BindingDB Monomer ID 423336BDBM423336(US10501458, Compound 1009)
Affinity DataIC50: 300nMAssay Description:Recombinant human IDO or TDO was incubated in 50 mM KPO4 (pH 7.0), 0.5 mM EGTA, 0.5 mM EDTA, 0.05% Triton X100, 20 mM ascorbate, 10 μM methylene...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/12/2020
Entry Details
US Patent

TargetTryptophan 2,3-dioxygenase(Human)
Iomet Pharma

US Patent
LigandChemical structure of BindingDB Monomer ID 423337BDBM423337(US10501458, Compound 1010)
Affinity DataIC50: 300nMAssay Description:Recombinant human IDO or TDO was incubated in 50 mM KPO4 (pH 7.0), 0.5 mM EGTA, 0.5 mM EDTA, 0.05% Triton X100, 20 mM ascorbate, 10 μM methylene...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/12/2020
Entry Details
US Patent

TargetTryptophan 2,3-dioxygenase(Human)
Iomet Pharma

US Patent
LigandChemical structure of BindingDB Monomer ID 423351BDBM423351(US10501458, Compound 1024)
Affinity DataIC50: 300nMAssay Description:Recombinant human IDO or TDO was incubated in 50 mM KPO4 (pH 7.0), 0.5 mM EGTA, 0.5 mM EDTA, 0.05% Triton X100, 20 mM ascorbate, 10 μM methylene...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/12/2020
Entry Details
US Patent

TargetIndoleamine 2,3-dioxygenase 1(Human)
Iomet Pharma

US Patent
LigandChemical structure of BindingDB Monomer ID 423350BDBM423350(US10501458, Compound 1023)
Affinity DataIC50: 300nMAssay Description:Recombinant human IDO or TDO was incubated in 50 mM KPO4 (pH 7.0), 0.5 mM EGTA, 0.5 mM EDTA, 0.05% Triton X100, 20 mM ascorbate, 10 μM methylene...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/12/2020
Entry Details
US Patent

TargetTryptophan 2,3-dioxygenase(Human)
Iomet Pharma

US Patent
LigandChemical structure of BindingDB Monomer ID 423352BDBM423352(US10501458, Compound 1025)
Affinity DataIC50: 300nMAssay Description:Recombinant human IDO or TDO was incubated in 50 mM KPO4 (pH 7.0), 0.5 mM EGTA, 0.5 mM EDTA, 0.05% Triton X100, 20 mM ascorbate, 10 μM methylene...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/12/2020
Entry Details
US Patent

TargetIndoleamine 2,3-dioxygenase 1(Human)
Iomet Pharma

US Patent
LigandChemical structure of BindingDB Monomer ID 423351BDBM423351(US10501458, Compound 1024)
Affinity DataIC50: 300nMAssay Description:Recombinant human IDO or TDO was incubated in 50 mM KPO4 (pH 7.0), 0.5 mM EGTA, 0.5 mM EDTA, 0.05% Triton X100, 20 mM ascorbate, 10 μM methylene...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/12/2020
Entry Details
US Patent

TargetTryptophan 2,3-dioxygenase(Human)
Iomet Pharma

US Patent
LigandChemical structure of BindingDB Monomer ID 423349BDBM423349(US10501458, Compound 1022)
Affinity DataIC50: 300nMAssay Description:Recombinant human IDO or TDO was incubated in 50 mM KPO4 (pH 7.0), 0.5 mM EGTA, 0.5 mM EDTA, 0.05% Triton X100, 20 mM ascorbate, 10 μM methylene...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/12/2020
Entry Details
US Patent

TargetIndoleamine 2,3-dioxygenase 1(Human)
Iomet Pharma

US Patent
LigandChemical structure of BindingDB Monomer ID 423348BDBM423348(US10501458, Compound 1021)
Affinity DataIC50: 300nMAssay Description:Recombinant human IDO or TDO was incubated in 50 mM KPO4 (pH 7.0), 0.5 mM EGTA, 0.5 mM EDTA, 0.05% Triton X100, 20 mM ascorbate, 10 μM methylene...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/12/2020
Entry Details
US Patent

TargetTryptophan 2,3-dioxygenase(Human)
Iomet Pharma

US Patent
LigandChemical structure of BindingDB Monomer ID 423350BDBM423350(US10501458, Compound 1023)
Affinity DataIC50: 300nMAssay Description:Recombinant human IDO or TDO was incubated in 50 mM KPO4 (pH 7.0), 0.5 mM EGTA, 0.5 mM EDTA, 0.05% Triton X100, 20 mM ascorbate, 10 μM methylene...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/12/2020
Entry Details
US Patent

TargetIndoleamine 2,3-dioxygenase 1(Human)
Iomet Pharma

US Patent
LigandChemical structure of BindingDB Monomer ID 423349BDBM423349(US10501458, Compound 1022)
Affinity DataIC50: 300nMAssay Description:Recombinant human IDO or TDO was incubated in 50 mM KPO4 (pH 7.0), 0.5 mM EGTA, 0.5 mM EDTA, 0.05% Triton X100, 20 mM ascorbate, 10 μM methylene...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/12/2020
Entry Details
US Patent

TargetTryptophan 2,3-dioxygenase(Human)
Iomet Pharma

US Patent
LigandChemical structure of BindingDB Monomer ID 423348BDBM423348(US10501458, Compound 1021)
Affinity DataIC50: 300nMAssay Description:Recombinant human IDO or TDO was incubated in 50 mM KPO4 (pH 7.0), 0.5 mM EGTA, 0.5 mM EDTA, 0.05% Triton X100, 20 mM ascorbate, 10 μM methylene...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/12/2020
Entry Details
US Patent

TargetIndoleamine 2,3-dioxygenase 1(Human)
Iomet Pharma

US Patent
LigandChemical structure of BindingDB Monomer ID 423363BDBM423363(N,3-dimethyl-5-{1-[7- (trifluoromethyl)imidazo[1, ...)
Affinity DataIC50: 398nMAssay Description:Compounds to be tested were serially diluted in ten 3-fold steps in DMSO starting from 10 mM DMSO stocks. Compound dilutions or DMSO alone were then ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/12/2020
Entry Details
US Patent

TargetIndoleamine 2,3-dioxygenase 1(Human)
Iomet Pharma

US Patent
LigandChemical structure of BindingDB Monomer ID 423364BDBM423364(6-amino-1,3-dimethyl-5-{4- [7- (trifluoromethyl)im...)
Affinity DataIC50: 794nMAssay Description:Compounds to be tested were serially diluted in ten 3-fold steps in DMSO starting from 10 mM DMSO stocks. Compound dilutions or DMSO alone were then ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/12/2020
Entry Details
US Patent

TargetIndoleamine 2,3-dioxygenase 1(Human)
Iomet Pharma

US Patent
LigandChemical structure of BindingDB Monomer ID 423365BDBM423365(5-[4-(1H-tetrazol-1- yl)piperidin-1-yl]-7- (triflu...)
Affinity DataIC50: 1.00E+3nMAssay Description:Compounds to be tested were serially diluted in ten 3-fold steps in DMSO starting from 10 mM DMSO stocks. Compound dilutions or DMSO alone were then ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/12/2020
Entry Details
US Patent

TargetIndoleamine 2,3-dioxygenase 1(Human)
Iomet Pharma

US Patent
LigandChemical structure of BindingDB Monomer ID 423342BDBM423342(US10501458, Compound 1015)
Affinity DataIC50: 1.74E+4nMAssay Description:Recombinant human IDO or TDO was incubated in 50 mM KPO4 (pH 7.0), 0.5 mM EGTA, 0.5 mM EDTA, 0.05% Triton X100, 20 mM ascorbate, 10 μM methylene...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/12/2020
Entry Details
US Patent

TargetIndoleamine 2,3-dioxygenase 1(Human)
Iomet Pharma

US Patent
LigandChemical structure of BindingDB Monomer ID 423340BDBM423340(US10501458, Compound 1013)
Affinity DataIC50: 1.74E+4nMAssay Description:Recombinant human IDO or TDO was incubated in 50 mM KPO4 (pH 7.0), 0.5 mM EGTA, 0.5 mM EDTA, 0.05% Triton X100, 20 mM ascorbate, 10 μM methylene...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/12/2020
Entry Details
US Patent

TargetIndoleamine 2,3-dioxygenase 1(Human)
Iomet Pharma

US Patent
LigandChemical structure of BindingDB Monomer ID 423354BDBM423354(US10501458, Compound 1027)
Affinity DataIC50: 1.74E+4nMAssay Description:Recombinant human IDO or TDO was incubated in 50 mM KPO4 (pH 7.0), 0.5 mM EGTA, 0.5 mM EDTA, 0.05% Triton X100, 20 mM ascorbate, 10 μM methylene...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/12/2020
Entry Details
US Patent

TargetTryptophan 2,3-dioxygenase(Human)
Iomet Pharma

US Patent
LigandChemical structure of BindingDB Monomer ID 423340BDBM423340(US10501458, Compound 1013)
Affinity DataIC50: 1.74E+4nMAssay Description:Recombinant human IDO or TDO was incubated in 50 mM KPO4 (pH 7.0), 0.5 mM EGTA, 0.5 mM EDTA, 0.05% Triton X100, 20 mM ascorbate, 10 μM methylene...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/12/2020
Entry Details
US Patent

TargetIndoleamine 2,3-dioxygenase 1(Human)
Iomet Pharma

US Patent
LigandChemical structure of BindingDB Monomer ID 423355BDBM423355(US10501458, Compound 1028)
Affinity DataIC50: 1.74E+4nMAssay Description:Recombinant human IDO or TDO was incubated in 50 mM KPO4 (pH 7.0), 0.5 mM EGTA, 0.5 mM EDTA, 0.05% Triton X100, 20 mM ascorbate, 10 μM methylene...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/12/2020
Entry Details
US Patent

TargetIndoleamine 2,3-dioxygenase 1(Human)
Iomet Pharma

US Patent
LigandChemical structure of BindingDB Monomer ID 423339BDBM423339(US10501458, Compound 1012)
Affinity DataIC50: 1.74E+4nMAssay Description:Recombinant human IDO or TDO was incubated in 50 mM KPO4 (pH 7.0), 0.5 mM EGTA, 0.5 mM EDTA, 0.05% Triton X100, 20 mM ascorbate, 10 μM methylene...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/12/2020
Entry Details
US Patent

TargetIndoleamine 2,3-dioxygenase 1(Human)
Iomet Pharma

US Patent
LigandChemical structure of BindingDB Monomer ID 423337BDBM423337(US10501458, Compound 1010)
Affinity DataIC50: 1.74E+4nMAssay Description:Recombinant human IDO or TDO was incubated in 50 mM KPO4 (pH 7.0), 0.5 mM EGTA, 0.5 mM EDTA, 0.05% Triton X100, 20 mM ascorbate, 10 μM methylene...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/12/2020
Entry Details
US Patent

TargetIndoleamine 2,3-dioxygenase 1(Human)
Iomet Pharma

US Patent
LigandChemical structure of BindingDB Monomer ID 423332BDBM423332(US10501458, Compound 1005)
Affinity DataIC50: 1.74E+4nMAssay Description:Recombinant human IDO or TDO was incubated in 50 mM KPO4 (pH 7.0), 0.5 mM EGTA, 0.5 mM EDTA, 0.05% Triton X100, 20 mM ascorbate, 10 μM methylene...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/12/2020
Entry Details
US Patent

Displayed 1 to 50 (of 72 total ) | Next | Last >>
Jump to: